According to the MHRA SmPC, no dose adjustment is required for patients with renal or hepatic impairment , though closer clinical monitoring is advised in severe renal impairment due to potential dehydration risk from gastrointestinal side effects
Most patients find the process easy and convenient, allowing them to maintain their regular routine without disruption
HOLST: The Gila monster, it was actually a great inspiration, so the study where we demonstrated the effect in diabetes was from 1993, and that's what convinced at least some of the pharmaceutical companies, and certainly Novo Nordisk in Denmark, that perhaps it was worthwhile working with this peptide, and that's why, that's when they started developing what later became liraglutide or Victoza
After 2 weeks, you may increase to 2 capsules for faster results
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older this is a notable exception to the BCBS-MI commercial exclusion